Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus observation after complete resection of Merkel cell carcinoma
NL-OMON50102Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Merkel cell carcinoma (MCC) comparing Nivolumab adjuvant therapy with Observation (2 arms). Primary endpoint: Disease-free survival at 12 months. Started May 2020; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON50102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50102.